跳至主要内容
临床试验/NCT00257413
NCT00257413已完成不适用

Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension

Zhejiang University1 个研究点 分布在 1 个国家开始时间: 2005年11月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
1

研究概览

简要总结

Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. In addition, clinical studies suggest that autogolous progenitor cells transplantation is feasible and safe in patients with ischemic disease. This study will investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous EPCs in patients with idiopathic pulmonary arterial hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of idiopathic pulmonary arterial hypertension
  • in New York Heart Association (NYHA) functional class II to III
  • a mean pulmonary artery pressure more than 30 mmHg on right heart catheterization
  • the ability to walk ≥50 m during a standardized 6-minute walk test.

排除标准

  • Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, NYHA functional class IV, major bleeding requiring blood transfusion, diabetes, renal dysfunction, and evidence for malignant diseases were excluded

研究者

发起方
Zhejiang University
申办方类型
Other

研究点 (1)

Loading locations...

相似试验